Gene:
F2
coagulation factor II (thrombin)

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.


Annotated Labels

  1. FDA Label for tamoxifen and ESR1,ESR2,F2,F5
  2. HCSC Label for ethinyl estradiol,norelgestromin and F2,F5,MTHFR,PROC,PROS1,SERPINC1

last updated 09/01/2016

1. FDA Label for tamoxifen and ESR1,ESR2,F2,F5

Actionable PGx
Full label available at DailyMed

Genes and/or phenotypes found in this label

  • Breast Neoplasms
    • Indications & usage section, Contraindications section, Warnings section, Adverse reactions section, Precautions section
    • source: PHONT
  • Death
    • Warnings section, Adverse reactions section, Precautions section
    • source: PHONT
  • Depression
    • Adverse reactions section
    • source: PHONT
  • Hot Flashes
    • Adverse reactions section
    • source: PHONT
  • Neoplasms
    • Indications & usage section, Contraindications section, Warnings section, Adverse reactions section, Precautions section
    • source: PHONT
  • Pain
    • Warnings section, Adverse reactions section, Precautions section
    • source: PHONT
  • ESR1
    • efficacy, Indications & usage section, Precautions section
    • source: U.S. Food and Drug Administration
  • ESR2
    • efficacy, Indications & usage section, Precautions section
    • source: U.S. Food and Drug Administration
  • F2
    • toxicity, Warnings section
    • source: U.S. Food and Drug Administration
  • F5
    • toxicity, Warnings section
    • source: U.S. Food and Drug Administration


PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the table.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page on the appropriate tab.

Links in the "Drugs" column lead to PharmGKB Drug Pages.

List of all variant annotations for F2

Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA
rs1799963 NC_000011.10:g.46739505G>A, NC_000011.9:g.46761055G>A, NG_008953.1:g.25313G>A, NM_000506.4:c.*97G>A, NM_001311257.1:c.*97G>A, XR_428840.2:n.1828G>A
G > A
SNP
No VIP available No Clinical Annotations available VA
rs3136516 NC_000011.10:g.46739206G>A, NC_000011.9:g.46760756G>A, NG_008953.1:g.25014G>A, NM_000506.4:c.1726-59G>A, NM_001311257.1:c.1678-59G>A, XR_428840.2:n.1588-59G>A, rs17847084, rs587776431
G > A
SNP
No VIP available No Clinical Annotations available VA
rs5896 NC_000011.10:g.46723453C>T, NC_000011.9:g.46745003C>T, NG_008953.1:g.9261C>T, NM_000506.4:c.494C>T, NM_001311257.1:c.446C>T, NP_000497.1:p.Thr165Met, NP_001298186.1:p.Thr149Met, XR_428840.2:n.538C>T, rs17645388, rs3136453, rs60714661
C > T
SNP
T165M
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Alternate Names:  prepro-coagulation factor II
Alternate Symbols:  None
PharmGKB Accession Id: PA157

Details

Cytogenetic Location: chr11 : p11.2 - p11.2
GP mRNA Boundary: chr11 : 46740743 - 46761056
GP Gene Boundary: chr11 : 46730743 - 46764056
Strand: plus

Visualization

UCSC has a Genome Browser that you can use to view PharmGKB annotations for this gene in context with many other sources of information.

View on UCSC Browser
The mRNA boundaries are calculated using the gene's default feature set from NCBI, mapped onto the UCSC Golden Path. PharmGKB sets gene boundaries by expanding the mRNA boundaries by no less than 10,000 bases upstream (5') and 3,000 bases downstream (3') to allow for potential regulatory regions.

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Platelet Aggregation Inhibitor Pathway, Pharmacodynamics
    Effects of antiplatelet drugs on platelet aggregation pathway.
  1. Warfarin Pathway, Pharmacodynamics
    Simplified diagram of the target of warfarin action and downstream genes and effects.

Curated Information ?

Evidence Gene
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
F2R
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
F2RL3
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available PW
GGCX

Curated Information ?

Curated Information ?

Publications related to F2: 14

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A pharmacogenetics-based warfarin maintenance dosing algorithm from northern chinese patients. PloS one. 2014. Chen Jinxing, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry. British journal of clinical pharmacology. 2011. Botton Mariana Rodrigues, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Predictive role of coagulation-balance gene polymorphisms in the efficacy of photodynamic therapy with verteporfin for classic choroidal neovascularization secondary to age-related macular degeneration. Pharmacogenetics and genomics. 2007. Parmeggiani Francesco, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacokinetics and pharmacodynamics of the dual FII/FX inhibitor BIBT 986 in endotoxin-induced coagulation. Clinical pharmacology and therapeutics. 2007. Leitner J M, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Oral contraceptive use, thrombophilia and their interaction in young women with ischemic stroke. Haematologica. 2006. Martinelli Ida, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Site-directed mutagenesis of coumarin-type anticoagulant-sensitive VKORC1: evidence that highly conserved amino acids define structural requirements for enzymatic activity and inhibition by warfarin. Thrombosis and haemostasis. 2005. Rost Simone, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Polymorphisms in factor II and factor VII genes modulate oral anticoagulation with warfarin. Haematologica. 2004. D'Ambrosio Rosa Lucia, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives. Contraception. 2004. Sidney Stephen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood. 2004. Shikata Eriko, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Venous thromboembolism in young women; role of thrombophilic mutations and oral contraceptive use. European heart journal. 2002. Legnani C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. JAMA : the journal of the American Medical Association. 2001. Psaty B M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Structure-activity and crystallographic analysis of a new class of non-amide-based thrombin inhibitor. Bioorganic & medicinal chemistry letters. 2000. Lu T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interaction between the G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arteriosclerosis, thrombosis, and vascular biology. 1999. Martinelli I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
High risk of cerebral-vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. The New England journal of medicine. 1998. Martinelli I, et al. PubMed

LinkOuts

NCBI Gene:
2147
OMIM:
176930
UCSC Genome Browser:
NM_000506
RefSeq RNA:
NM_000506
RefSeq Protein:
NP_000497
RefSeq DNA:
NG_008953
NT_009237
UniProtKB:
THRB_HUMAN (P00734)
Ensembl:
ENSG00000180210
GenAtlas:
F2
GeneCard:
F2
MutDB:
F2
ALFRED:
LO000605L
HuGE:
F2
Comparative Toxicogenomics Database:
2147
ModBase:
P00734
HumanCyc Gene:
HS11470
HGNC:
3535

Common Searches